Dr. Carlos Collet, MD, Ph.D., Appointed Director of Cardiovascular Imaging, Physiology, and Translational Therapeutics at CRF®

In a significant stride toward advancing cardiovascular medicine, the Cardiovascular Research Foundation® (CRF®) proudly announces the appointment of Dr. Carlos Collet as Director of Cardiovascular Imaging, Physiology, and Translational Therapeutics. Dr. Collet, a preeminent figure in interventional cardiology and cardiovascular imaging, will lead CRF®’s efforts to integrate pioneering research with clinical applications, thereby reinforcing the foundation’s role as a global epicenter of cardiovascular innovation and education.

Dr. Collet’s tenure comes at a pivotal moment when non-invasive cardiovascular imaging modalities such as coronary computed tomography angiography (CCTA) are redefining diagnostic paradigms. With his expertise, CRF® aims to harness these advances to improve patient stratification and outcomes in coronary artery disease. His leadership will be integral in bridging the gap between cutting-edge imaging techniques and the nuanced understanding of coronary physiology, fostering an environment where translational science accelerates therapeutic innovation.

The appointment reflects CRF®’s commitment to elevating the scientific rigor and clinical impact of its cardiovascular imaging and physiology programs. Dr. Juan F. Granada, President and CEO of CRF®, emphasized the transformative potential of Dr. Collet’s arrival, highlighting how his knowledge of coronary CT technology embodies the future of cardiovascular diagnostics. Dr. Granada underlined the strategic importance of embedding advanced imaging within CRF®’s multifaceted approach to cardiovascular care and research.

At the core of Dr. Collet’s vision is the expansion of CRF®’s imaging portfolio through the introduction of novel coronary and endovascular services. Alexandra Popma, MD, Executive Director of CRF®’s Clinical Trials Center, expressed enthusiasm for the innovative trajectory Dr. Collet will foster. She noted that his combined clinical acumen and scientific leadership are essential for refining imaging capabilities, which are critical for elucidating cardiovascular pathophysiology and enhancing precision medicine strategies.

Dr. Collet’s distinguished background encompasses more than 300 peer-reviewed publications, reflecting his prolific contribution to interventional cardiology, vascular imaging, and translational research. His recent leadership at the Cardiovascular Center OLV Aalst’s catheterization laboratory in Belgium underscored his expertise in applying physiological measurements alongside imaging data to complex coronary artery disease cases. This dual focus on anatomy and physiology is pivotal in advancing personalized treatment approaches.

His educational journey spans multiple continents and specialties, with foundational medical training at the Dante Pazzanese Institute of Cardiology in São Paulo and advanced postgraduate study in cardiac computed tomography angiography at Holy Cross Hospital in Florida. Crucially, Dr. Collet earned a PhD from the University of Amsterdam with research concentrated on the integration of coronary imaging and physiology—a specialty that positions him uniquely to spearhead translational efforts at CRF®.

The integration of coronary CT imaging with physiological measurements like fractional flow reserve (FFR) represents a transformational approach in cardiovascular medicine. By combining anatomical and functional assessments, clinicians can more precisely stratify risk and tailor interventional strategies. Dr. Collet’s expertise in deploying these hybrid modalities will likely accelerate the adoption of evidence-based, minimally invasive diagnostics that reduce procedural complications and improve long-term outcomes.

Innovation within CRF® under Dr. Collet’s direction will not be limited to technological deployment. He advocates for the creation of multidisciplinary platforms that unify translational science, biomedical engineering, and clinical practice. Such platforms are designed to facilitate rapid bench-to-bedside translation of discoveries, integrating artificial intelligence and machine learning to further refine diagnostic precision and predict therapeutic responses.

Dr. Collet’s vision extends to education, ensuring that CRF® remains at the forefront of training healthcare professionals globally. By enhancing curriculum content with the latest imaging and physiology techniques, CRF® aims to cultivate a new generation of cardiologists skilled in interpreting complex diagnostic data and implementing personalized therapies. This educational mission aligns with the foundation’s broader goal of disseminating evidence-based knowledge to improve survival rates and quality of life for patients worldwide.

The synergy between imaging modalities, physiological assessments, and translational therapeutics represents a frontier with immense potential. By uniting these disciplines under Dr. Collet’s leadership, CRF® endeavours to catalyze innovation, foster collaborative research networks, and promote clinical trials that validate new diagnostic and therapeutic strategies. These efforts will ultimately lead to more nuanced and effective management of cardiovascular diseases, including ischemic heart disease and heart failure.

Dr. Collet’s appointment signals a commitment to advancing the cardiovascular field through integrative approaches that leverage technology and clinical insight. As cardiovascular diseases remain a leading cause of morbidity and mortality globally, breakthroughs in imaging and physiology are essential to meet the challenges of early detection and treatment optimization. CRF®’s leadership in this arena is expected to have far-reaching impact, influencing practice guidelines and elevating standards of care worldwide.

Expressing his enthusiasm, Dr. Collet stated, “Joining CRF® allows me to contribute to a mission grounded in innovation, science, and education. We stand on the cusp of transformative change in cardiovascular medicine, driven by imaging and translational research. Together, we will expand our coronary and endovascular services, develop new diagnostic platforms, and foster personalized care paradigms that improve patient outcomes on a global scale.” His appointment exemplifies CRF®’s forward-looking strategy to harness expertise and technology for the betterment of cardiovascular health internationally.

News Publication Date: September 9, 2025

Web References:
https://mediasvc.eurekalert.org/Api/v1/Multimedia/028f5ce5-58eb-4308-9387-cd55c33520c5/Rendition/low-res/Content/Public